XYL Stock Analysis: Xylem | NYSE
Specialty Industrial Machinery | NYSE, USA | Market Cap: 22.945m USD | 12M Return: -35.2% | US98419M1009 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 308M
EPS Trend: 99.7%
Qual. Beats: 0
Rev. Trend: 90.5%
Qual. Beats: -1
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.9 years of data, until 10/2026
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.
Xylem Inc. (NYSE: XYL) is a global water technology company that designs, manufactures, and services engineered products and solutions for utility, industrial, and residential/commercial customers. The company operates through four segments: Water Infrastructure, Applied Water, Measurement and Control Solutions, and Water Solutions and Services, and sells a broad portfolio of brands including Flygt, Sensus, Wedeco, Bell & Gossett, and YSI.
Its offerings span water and wastewater pumps, filtration and treatment equipment, smart meters, network communications, data analytics, and cloud-based monitoring platforms, as well as services such as preventative maintenance, mobile dewatering, environmental remediation, and municipal odor and corrosion control. This mix of hardware, software, and recurring service revenue reflects the shift across the water sector toward digital, data-driven infrastructure management.
Xylem is classified within the Industrials sector (Industrial Machinery & Supplies & Components) and is a large-cap U.S. issuer listed on the NYSE since its 2011 spin-off, when it was renamed from ITT WCO, Inc. The company is headquartered in Washington, D.C., and serves customers worldwide.
- US Infrastructure Law funding accelerates municipal water capex
- Evoqua acquisition expands industrial water treatment revenue and margins
- Smart metering adoption drives Measurement and Control Solutions segment growth
| Net Income: 1.07b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA -0.03 > 1.0 |
| NWC/Revenue: 12.25% < 20% (prev 24.42%; Δ -12.17% < -1%) |
| CFO/TA 0.07 > 3% & CFO 1.27b > Net Income 1.07b |
| Net Debt (2.32b) to EBITDA (1.94b): 1.20 < 3 |
| Current Ratio: 1.39 > 1.5 & < 3 |
| Outstanding Shares: last quarter (233.0m) vs 12m ago -4.53% < -2% |
| Gross Margin: 39.79% > 18% (prev 38.23%; Δ 1.57% > 0.5%) |
| Asset Turnover: 52.33% > 50% (prev 51.43%; Δ 0.91% > 0%) |
| Interest Coverage Ratio: 36.29 > 6 (EBIT TTM 1.38b / Interest Expense TTM 38.0m) |
| A: 0.06 (Total Current Assets 3.95b - Total Current Liabilities 2.84b) / Total Assets 17.3b |
| B: 0.24 (Retained Earnings 4.15b / Total Assets 17.3b) |
| C: 0.08 (EBIT TTM 1.38b / Avg Total Assets 17.3b) |
| D: 1.51 (Book Value of Equity 10.3b / Total Liabilities 6.82b) |
| Altman-Z'' = 3.32 = A |
| DSRI: 1.07 (Receivables 1.97b/1.80b, Revenue 9.06b/8.89b) |
| GMI: 0.96 (GM 38.23% / 39.79%) |
| AQI: 1.04 (AQ_t 0.70 / AQ_t-1 0.68) |
| SGI: 1.02 (Revenue 9.06b / 8.89b) |
| TATA: -0.01 (NI 1.07b - CFO 1.27b) / TA 17.3b) |
| Beneish M = -2.97 (Cap -4..+1) = A |
As of November 15, 2026, the stock is trading at USD 94.18 with a total of 1,862,706 shares traded. Over the past week, the price has changed by -3.73%, over one month by -8.15%, over three months by -21.43% and over the past year by -35.15%.
Current recommended Stop Loss: 89.90 (which is 4.5% or 1.3 ATR below the current price).
Xylem has received a consensus analysts rating of 4.05. Therefore, it is recommended to buy XYL.
- StrongBuy: 10
- Buy: 3
- Hold: 7
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 125.4 | 33.2% |
P/E Trailing = 22.184
P/E Forward = 17.2712
P/S = 2.5328
P/B = 2.2567
P/EG = 1.3495
Revenue TTM = 9.06b USD
EBIT TTM = 1.38b USD
EBITDA TTM = 1.94b USD
Long Term Debt = 2.37b USD (from longTermDebt, last quarter)
Short Term Debt = 530.0m USD (from shortTermDebt, last quarter)
Debt = 3.03b USD (from shortLongTermDebtTotal, last quarter) + Leases 131.0m
Net Debt = 2.32b USD (calculated: Debt 3.03b - CCE 708.0m)
Enterprise Value = 25.3b USD (22.9b + Debt 3.03b - CCE 708.0m)
Interest Coverage Ratio = 36.29 (Ebit TTM 1.38b / Interest Expense TTM 38.0m)
EV/FCF = 27.43x (Enterprise Value 25.3b / FCF TTM 921.0m)
FCF Yield = 3.65% (FCF TTM 921.0m / Enterprise Value 25.3b)
FCF Margin = 10.17% (FCF TTM 921.0m / Revenue TTM 9.06b)
Net Margin = 11.86% (Net Income TTM 1.07b / Revenue TTM 9.06b)
Gross Margin = 39.79% ((Revenue TTM 9.06b - Cost of Revenue TTM 5.45b) / Revenue TTM)
Gross Margin QoQ = 41.21% (prev 41.22%)
Tobins Q-Ratio = 1.46 (Enterprise Value 25.3b / Total Assets 17.3b)
Interest Expense / Debt = 1.26% (Interest Expense 38.0m / Debt 3.03b)
Taxrate = 20.13% (270.0m / 1.34b)
NOPAT = 1.10b (EBIT 1.38b * (1 - 20.13%))
Current Ratio = 1.39 (Total Current Assets 3.95b / Total Current Liabilities 2.84b)
Debt / Equity = 0.29 (Debt 3.03b / totalStockholderEquity, last quarter 10.3b)
Debt / EBITDA = 1.20 (Net Debt 2.32b / EBITDA 1.94b)
Debt / FCF = 2.52 (Net Debt 2.32b / FCF TTM 921.0m)
Total Stockholder Equity = 10.8b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.20% (Net Income 1.07b / Total Assets 17.3b)
RoE = 9.96% (Net Income TTM 1.07b / Total Stockholder Equity 10.8b)
RoCE = 10.49% (EBIT 1.38b / Capital Employed (Equity 10.8b + L.T.Debt 2.37b))
RoIC = 7.56% (NOPAT 1.10b / Invested Capital 14.6b)
WACC = 7.30% (E(22.9b)/V(26.0b) * Re(8.13%) + D(3.03b)/V(26.0b) * Rd(1.26%) * (1-Tc(0.20)))
Discount Rate = 8.13% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -69.12 | Cagr: -1.94%
[DCF] Terminal Value 75.38% ; FCFF base≈922.6m ; Y1≈923.1m ; Y5≈970.8m
[DCF] Fair Price = 55.78 (EV 15.1b - Net Debt 2.32b = Equity 12.8b / Shares 229.3m; r=8.35% [WACC [floored]]; 5y FCF grow -0.43% → 2.50% )
EPS Correlation: 99.67 | EPS CAGR: 16.00% | SUE: -0.58 | # QB: 0
Revenue Correlation: 90.48 | Revenue CAGR: 6.58% | SUE: -1.50 | # QB: -1
EPS current Quarter (2027-03-31): EPS=1.15 | Chg30d=-4.67% | Revisions=-25% | Analysts=14
EPS current Year (2026-12-31): EPS=5.43 | Chg30d=-4.18% | Revisions=-10% | GrowthEPS=+6.9% | GrowthRev=-0.9%
EPS next Year (2027-12-31): EPS=5.90 | Chg30d=-5.54% | Revisions=-50% | GrowthEPS=+8.7% | GrowthRev=+3.9%
[Analyst] Revisions Ratio: -39% (up=4, down=11)